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Abstract 
 
Background: Metformin intoxication can potentially originate a lactic acidosis of 
variable severity, but possibly fatal, diagnosis and prompt treatment of which are 
crucial. The difficulty in establishing a clear cause and effect relationship arises from 
the multitude of biologic actions exerted by metformin. 
Objective: Review of literature in order to compile the current knowledge regarding 
the diagnosis, management and prognosis of metformin associated lactic acidosis. 
Methods: Data were collected using PubMed database researching the terms 
“metformin” and “lactic acidosis”. After selection of 29 titles and abstracts, 25 full-
text articles were consulted. 
Results: The direct mechanism through which metformin induces lactic acidosis 
remains incompletely understood. Its anti-gluconeogenic actions and respiratory chain 
inhibition appear to play a key role. Prognosis depends mainly on the presence of 
comorbid conditions, rather than the degree of either metformin or lactate 
accumulation. And independent variable that seems to influence prognosis is 
prothrombin time at admission. Prolonged dialysis appears to be an adequate 
treatment. 
Conclusions: Prompt recognition and institution of both supportive treatment and 
renal replacement techniques are appropriate regarding the management of metformin 
associated lactic acidosis, being the most relevant aspects in improving the outcome 
of this condition.  
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Resumo 
 
Introdução: A intoxicação por metformina tem o potencial de  originar uma acidose 
láctica de gravidade variável, mas potencialmente fatal, cujo expedito reconhecimento 
e instituição do tratamento são fulcrais. A dificuldade de determinação de uma relação 
direta de causa-efeito advém da miríade de ações biológicas exercidas pela 
metformina, esclarecimento das quais continua em expansão.  
Objetivo: Revisão da literatura com o objectivo de compilar o conhecimento atual 
relativo ao reconhecimento, tratamento e prognóstico da acidose láctica associada à 
metformina. 
Métodos: Pesquisa bibliográfica na base de dados científica PubMed utilizando os 
termos “metformina” e “acidose láctica”, com seleção inicial de 29 artigos, e 
utilização de 25 destes na realização do presente trabalho. 
Resultados: O mecanismo direto através do qual a metformina induz acidose láctica e 
o modo como isto se traduz no quadro clínico continuam por elucidar totalmente. As 
ações anti-gliconeogénicas bem como a inibição da cadeia respiratória parecem 
desempenhar um papel preponderante. O prognóstico parece amplamente dependente 
da presença de comorbilidades e não do grau de acumulação de metformina ou 
lactato. Uma variável independente que aparenta valor prognóstico é o tempo de 
protrombina à admissão. O tratamento com diálise de longa duração mostra-se 
adequado. 
Conclusões: O rápido reconhecimento desta entidade e pronta instituição de 
tratamento de suporte e técnicas de substituição renal afiguram-se adequados na 
gestão da intoxicação aguda por metformina, sendo os aspectos mais relevantes na 
melhoria do prognóstico. 
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Introduction 
 
Metformin has a well-established role as the mainstay of type 2 diabetes 
mellitus pharmacologic therapy, either in alone or in combination with other agents, 
due to its extensive track record of safety and tolerability, low cost, and efficacy[1]. 
Despite the favourable safety profile, metformin therapy may be associated with the 
development of lactic acidosis, a scenario that must be kept in mind considering the 
amount of patients potentially at risk- i.e. type 2 diabetics under metformin therapy. 
With an estimated incidence ranging from 3 to 47 cases per 100.000 patient-
years[2,3,4], this clinical entity carries an elevated mortality rate, up to 50% in some 
series[2]. Metformin intoxication by overdose, either accidental or intentional, is 
uncommon. The majority of cases occur when a precipitating event or predisposing 
condition, while under therapeutic metformin levels, impair the renal clearance of the 
drug[2]. 
The mechanism underlying metformin-induced lactic acidosis remains 
incompletely understood, perhaps as a consequence of the difficulty, over the years, 
of clearly establishing metformin’s exact mode of action. Importantly, recent 
investigations have carried out significant advances in pinpointing specific molecular 
targets, focusing on how metformin exerts its therapeutic actions. However, the 
relationship between the abnormally elevated levels of metformin and the 
development of lactic acidosis is neither straightforward nor linear, and a plenitude of 
coexisting conditions usually confounds the clinical picture. 
Metformin intoxication presentation is unspecific, frequently affected by 
eventual coexisting pathologies, and most commonly characterized by vomiting and 
diarrhoea[3]; with hypothermia and respiratory failure also being reported[5], and 
eventually progressing to severe lactic acidosis. There may be, however, 
asymptomatic presentations, which contributes to the difficulty of early recognition of 
the clinical picture and expeditious institution of therapeutic manoeuvres[6]. 
After the diagnosis is established with fair certainty, haemodialysis appears to 
constitute the most appropriate course of action regarding treatment of acute 
metformin intoxication, and its early institution seems advisable[7], with prolonged 
haemodialysis being the method of choice[2;8].   
The purpose of this review is to compile the current understanding regarding 
metformin intoxication, its recognition and management, and also the possible 
prognostic indicators amenable to give some insight into individual outcomes of this 
unusual, but conceivably fatal condition. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Metformin- Mode of action and induction of lactic acidosis 
 
Despite having been in clinical use for over 60 years, the full spectrum of 
metformin biologic actions has been notoriously laborious to establish. After 
absorption through the high small-intestine mucosa, this drug circulates chiefly 
unbound to plasma proteins, being concentrated in both enterocytes and hepatocytes, 
and is excreted by the kidney, without undergoing measurable metabolization[9]. 
Inhibition of gluconeogenesis by metformin reliably decreases endogenous 
glucose production[9], and the main mechanism by which this is accomplished has 
recently been elucidated by a series of studies by Madijaru et al. Through an array of 
experiments undertaken in rats, infusion of metformin to levels equivalent to those in 
the therapeutic range achieved in type 2 diabetics, it has been established that the non-
competitive inhibition of the mitochondrial enzyme glycerophosphate dehydrogenase, 
which catalyses the conversion of glycerol-3-phosphate to dyhidroxyacetone 
phosphate (DHAP), constitutes the main mode of action of this drug[1,10]. Notably, the 
change in cytosolic NADH-NAD ratio secondary to the diminished levels of DHAP 
down-regulates the gluconeogenic pathway by impairing the conversion of lactate to 
pyruvate, thus preventing the use of both pyruvate as well as glycerol as 
gluconeogenic precursors[10], decreasing the generation of glucose, and mediating the 
subsequent hypoglycemic effect of metformin (Fig.	   1).  
 
 
Figure 1. Metformin mode of action 	  
Metformin	  inhibits	  the	  mitochondrial	  isoform	  of	  the	  enzyme	  glycerophosphate dehydrogenase thus altering the	  NADH-
NAD ratio due to decreased levels of DHAP.  This impairs the conversion of lactate to pyruvate, blunting gluconeogenesis 
and therefore hepatic glucose output. mGDP: mitochondrial glycerophosphate dehydrogenase; cGDP: cytoplasmatic 
glycerophosphate dehydrogenase DHAP: dyhidroxyacetone phosphate; LDH: lactate dehydrogenase.	  
Despite the elucidation of the aforementioned mechanism of action, 
metformin has remarkably far more biologic effects. Gene expression modulation has 
also been postulated to play an important role in the hypoglycemic effect of this drug. 
Canton et al have reported that metformin induced, AMPK-dependent, increase in the 
levels of SIRT1 and GCN5, key regulators of gluconeogenic pathway gene 
expression, constitute a potential mechanism of inhibition of hepatic gluconeogenesis 
by metformin[11]. In addition, AMPK-mediated induction in the expression of the 
orphan nuclear receptor SHP has also been implicated as a mechanism of inhibition of 
gluconeogenic gene activity, namely PEPCK and G6Pase down-regulation, secondary 
to the up-regulation of SHP[12]. Nonetheless, many other proposed mechanism of 
action abound, consequent of many studies undertaken over the years. These range 
from delayed intestinal absorption of glucose, interference with glucagon signalling, 
and increased enterocyte generation of lactate, to increased levels of glucagon-like 
peptide 1 and inhibition of mitochondrial complex I[1]. This plethora of proposed 
biologic effects underscores the complexity of the full clinical spectrum of metformin 
actions, both therapeutic as well as in the context of metformin intoxication. 
Lactic acidosis, defined as an arterial pH≤7.35 and a lactate level ≥5 
mmol/L[13], secondary to the administration of metformin- the so-called metformin-
associated lactic acidosis (MALA)- is a notoriously rare occurrence, taking into 
account the prevalent use of the drug[6,7]. The circumstances under which metformin 
may induce lactic acidosis are either accumulation of the drug due to a medical 
condition impairing the ability of excretion, in patients taking therapeutic doses; or 
the ingestion, accidental or voluntary, of an excessive amount, acutely surpassing the 
excretory capacity, even though a cut-off value of the necessary quantity to induce 
toxicity remains elusive[6]. 
The role played by metformin in the induction of lactic acidosis, and the 
mechanisms involved in this toxicity haven’t been thus far fully clarified. It is 
important to note that metformin has inherited a class-effect, given that the 
development of lactic acidosis has been well-established following phenformin 
administration, another biguanide, through inhibition of oxidative phosphorylation, 
both peripheral and hepatic, with ensuing potentiation of anaerobic metabolism and 
lactate generation[3]. At the hepatocyte level, at least, this effect appears to be related 
to the organic cation transporter 1-mediated uptake of biguanides and intracellular 
concentration of the drug[14]. Even so, it must be emphasized that the potential of 
metformin to induce lactic acidosis is reportedly 140 times less than that of 
phenformin[14]. 
Several studies have focused on the inhibitory effect of metformin on the 
components of the respiratory chain. This effect on oxygen consumption has been 
observed in patients following biguanide intoxication, in which mitochondrial toxicity 
impairs tissue oxygen consumption despite adequate O2 delivery[15]. Such toxicity has 
also been reported to induce lactate production in peripheral blood monocytes and 
platelets, via specific inhibition of mitochondrial complex I[16]. This global 
impairment of oxygen consumption has been further validated by animal model 
studies, where it was observed that metformin, in addition to induction of lactic 
acidosis, also caused widespread mitochondrial dysfunction, both at the hepatic and 
peripheral level[17]. Further substantiation of the respiratory inhibition by metformin 
ensues from the fact that lactic acid infusion failed to translate into blunting of oxygen 
consumption at the cellular level[17], revealing a direct effect of the drug, thus 
exculpating lactate from this responsability. These findings highlight that, in spite of 
the central part played by the liver in both metformin therapeutic and toxic actions, 
the peripheral activity of this drug is key to the understanding of the whole clinical 
picture of metformin intoxication.  
 
 
Metformin intoxication- Clinical presentation and diagnosis 
 
The clinical picture of acute metformin intoxication presents itself as a 
diagnostic challenge due to its remarkably uncharacteristic features. First and 
foremost, the differential diagnosis of lactic acidosis is vast[18], and a myriad of 
conditions course with its development (Table I)[18]. Therefore, an increased arterial 
lactate level coupled with reduced pH in a patient under metformin therapy is not 
necessarily indicative of MALA. Further complicating this diagnosis is the fact that 
the majority of patients at risk of developing MALA- i.e. metformin-treated type 2 
diabetics- have an inherently higher probability of lactic acidosis unrelated to drug 
therapy[3].  
In the literature, the most commonly related features of MALA are of 
gastrointestinal nature, including anorexia, nausea, vomiting, abdominal pain, and 
diarrhoea[3, 5]. The occurrence of hypothermia, hypotension and respiratory failure in 
severe cases have also been reported[5], as well as asymptomatic presentations[6]. 
Hence, the difficulty of recognition of MALA cannot be overstated, and a 
considerable index of suspicion and awareness of this entity are fundamental. 
In the presence of a patient with suspected MALA, it should be kept in mind 
that the overwhelming majority of cases occur in individuals with an intrinsically 
elevated risk of lactic acidosis related to underlying conditions, and that 
fundamentally all diabetic patients may develop the latter when their circulatory 
system is put under stress[3]. Also obscuring an eventual diagnosis of MALA is the 
fact that plasma metformin levels, besides not being readily available in most 
emergency settings[7,19,20], are surprisingly not as reliable as it would appear. The 
finding of low plasma concentrations of the drug should be interpreted as a negative 
predictor of MALA[7], but the opposite, however, might not be applicable. In fact, the 
relation between serum metformin levels and hiperlactacidemia is far from being 
linear[7,19], and even concentrations within the normal therapeutic range have been 
reported[19] in patients with MALA. Nonetheless, MALA should be pondered in the 
differential diagnosis of any patient presenting with a metabolic acidosis and elevated 
lactate levels, after systematic exclusion of other precipitating causes[20], and in 
accordance with the history of metformin dosage and latest administration[7]. It should 
be kept in mind, however, that the preceding criteria allow only for the establishment 
of a probable diagnosis of MALA, but even so this should prompt expeditious 
institution of therapeutic measures in order to establish the adequate management of 
such patients. 
 
  
   
Table I. Causes of lactic acidosis Shock	  (cardiogenic	  or	  hypovolemic),	  heart	  failure,	  trauma	   Metformin	  Sepsis	   Nucleoside	  reverse-­‐transcriptase	  inhibitors	  Severe	  hypoxemia	   Cocaine	  CO	  poisoning	   Methanol,	  ethylene	  glycol,	  diethylene	  glycol,	  propylene	  glycol	  Severe	  anemia	   Salicylates	  Strenuous	  exercise,	  seizures	   Cyanide	  Diabetes	  mellitus	   Β2-­‐agonists	  Malignancy	   Propofol	  Liver	  disease	   Thiamine	  deficiency	  Pheochromocytoma	   	  
Management strategies 
 
Treatment of suspected MALA entails intensive care-based management, 
being the primary objective the restitution of acid-base equilibrium, with emphasis on 
enhancement of ventilation in order to allow compensation of the acidosis[7]. From 
this supportive approach stems the importance of addressing any underlying 
conditions that may hinder patient recovery[2,5,21], as well as maintenance of 
circulatory integrity with the use of vasopressor medication[22]. In the exceptional 
instances where the diagnosis of MALA is made following ingestion of a large 
amount of metformin, activated charcoal might be used in order to prevent further 
intestinal absorption of the drug[6,8]. 
Traditionally, renal replacement techniques have been advocated as a vital 
component of managing such patients, and several studies have reported its usefulness 
in this setting. Lactate and metformin are both effectively dialyzable[7], but this does 
not in itself grant haemodialysis its value in the management of MALA. Rather the 
rapid correction of volume, osmolality, and pH derangements in an acutely ill subject 
are the main mechanism through which renal substituting interventions exert their 
beneficial effect[7,13,23]. Considering metformin’s tissue accumulation and high 
volume of distribution[8], and the fact that its elimination occurs in two distinct 
phases[2], it is deemed as generally more effective to institute prolonged 
haemodialysis in this setting[2,23]. Regarding modalities of renal replacement 
therapies, comparison between conventional haemodialysis (HD) and continuous 
veno-venous haemodialysis (CVVHD) has failed to yield results favouring one or the 
other[23], being the latter best suited for patients whose baseline cardiovascular status 
impedes the use of HD[8,23].  Notwithstanding, no clear agreement exists between 
peers considering the systematic implementation of neither this measure nor the exact 
parameters that warrant it in the context of MALA. Namely, there is no strict, widely 
applicable set of rules regarding when to institute dialysis. However, some have been 
proposed as possible indications, specifically the existence of serious concomitant 
pathology, the degree of criticality at presentation, a blood pH value lower than 7.1, 
as well as failure of supportive treatment, advent of renal insufficiency and, finally, 
the presence of a fluid overload[23].  
 
  
Prognosis 
 
Predicting the outcome of MALA has traditionally been notoriously difficult. 
Given that this condition arises from metformin intoxication (either from failure of 
excretion or from excessive ingestion) originating a lactic acidosis, it would stand to 
reason that the plasmatic levels of these substances could have significant 
implications. However, this has not been indeed verified by most studies. Regarding 
metformin, no clear correlation between its plasmatic levels and either degree of 
neither lactacidemia nor mortality has been systematically established[2,22,24]. Also 
noteworthy is the finding that the degree of renal impairment as measured by seric 
creatinine did neither increase the risk of mortality nor predict the degree of 
accumulation of both lactate and metformin[24]. The prognostic impact of renal 
replacement techniques, despite being generally indicated, is yet to be fully evaluated, 
and no concrete data exist on their effect on survival. In addition, it has been reported 
equal survival between patients who had undergone dialysis compared to those who 
had not[25].  Adding to the intricacy of prognostic evaluation, better outcomes have 
actually been observed in the patients whose blood metformin concentrations were 
actually higher compared with non-survivors[4]. 
Documented variables that adversely impact mortality are sepsis, acute 
cardiovascular occurrences and end-stage liver failure[24], as well as a decreased 
prothrombin time (PT) upon admission[2]. The latter measurement has shown 
predictive power for mortality[2] in the absence of underlying chronic hepatic 
conditions, possibly indicating a direct acute hepatic damage attributable to 
metformin. PT determination might consequently be a valuable tool when risk 
stratification is undertaken in MALA patients.  
Given the limited number of studies, it is rather difficult to provide well-
defined signs for increased risk of unfavourable outcomes. What currently has been 
established is that prognosis depends mostly on the severity of the underlying 
conditions[2,4,23]. Also, when comparing MALA ensuing ingestion of an excessive 
amount of metformin (voluntary or otherwise) with MALA resulting from drug under 
excretion due to underlying illness, the prognosis of the former appears much more 
favourable[2,7] if prompt management is commenced. It has also been reported that, 
taking into account the degree of acidemia, the prognosis of MALA isn´t as bleak as 
the prognosis of lactic acidosis resulting from other causes[22]. 
Stemming from the notions above, the management of MALA and 
improvement of outcomes relies essentially on the recognition of metformin as an 
aetiological factor, either causative or precipitating; the rapid evaluation of functional 
status by use of one of several scales, such as the Logistic Organ Dysfunction System 
(LODS), Simplified Acute Physiology Score II (SAPS II) and Sequential Organ 
Failure Assessment (SOFA); and finally, the hasty institution of supportive care and 
specific therapy.  
 
Conclusions 
 
The cumulative understanding of the full spectrum of metformin biologic 
actions and the increasing awareness of MALA merit further studies in order to fully 
elucidate the true role played by this drug. The difficulty of establishing clear 
protocols regarding the management of MALA is partially explained by the scarcity 
of prospective works in which careful patient selection and focused laboratory tests- 
mainly metformin plasma level determination- have taken place. Thus, an effort 
should be made in designing and implementing studies in order to fully characterize 
this condition and accompanying clinical picture. 
Throughout literature, the severity of MALA has largely been overstated, 
perhaps due to the history of severe lactic acidosis induced by phenformin, another 
biguanide. However, regardless of the rarity of severe metformin intoxication, it 
assumes great importance due to the vast number of patients potentially at risk, most 
of whom are afflicted by serious comorbid conditions. This is underscored also by the 
fact that prognosis is largely influenced by the patient’s health status and, unlike true 
over dosage in an otherwise healthy individual, MALA in the setting of underlying 
pathology adds to a much poorer outcome. Given that true parameters of achieving a 
diagnosis with certainty are lacking, hasty institution of supportive care and renal 
replacement techniques appears adequate in the management of this condition, and 
doing so may be key to improving individual outcomes. 
Keeping this in mind, it is crucial to state that, despite the clinical implications 
of MALA, metformin is a drug with more than proven effectiveness, and its benefits 
are not limited to its hypoglycemic control in diabetics, exerting multiple therapeutic 
actions in various organ systems. It has been for years the foundation of treatment of 
type 2 Diabetes, and the experience with its use coupled with metformin’s safety 
profile in most situations, as well as an ever-expanding knowledge of its actions, 
mean that it most likely should remain so.  
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